Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can your genes predict prostate Cancer's next move?

NCT ID NCT05810467

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers want to see if men with a higher genetic risk for prostate cancer are more likely to have their cancer progress over time. The goal is to better understand who can safely stay on surveillance and who may need treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict which men with low-risk prostate cancer can safely avoid treatment and which need closer monitoring.
What could go wrong
This is an observational study, not a treatment trial. It will not directly improve outcomes for participants, and results may take years to influence clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Control group (i.e., no known high PrCa risk): 100 men * Men at genetically higher PrCa risk: 100 men

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Men ≥18 years old under the care of an Active Surveillance clinic. * Known diagnosis of PrCa, deemed suitable for Active surveillance at multi-disciplinary meeting (MDT). * Men at genetically higher PrCa risk who are either: (1) Men of any ancestry with a positive family history of PrCa defined as: * Having a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years * Having two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years * Having three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age Or (2) Men of Black African or Black African-Caribbean ancestry defined as: * Both parents and all 4 grandparents from that origin Or (3) Men of any ancestry with a pathogenic mutation in a gene thought to cause a higher risk of prostate cancer: (including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in appendix A) Or (4) Men of any ancestry with a high genetic risk (common and/or rare variants) for PrCa resulting in a RR of ≥2 of PrCa * Men of any ancestry with no known high risk genetic factors who have been diagnosed with low grade PrCa and deemed suitable for Active Surveillance at multi-disciplinary meeting (control group) as defined in the 4 criteria above. * Who performance status 0-2 * Absence of any psychological, familial, sociological, or geographical situation potentially hampering compliance with the study protocol and follow-up schedule. Exclusion Criteria * No PrCa diagnosis * PrCa diagnosis that is not deemed suitable for active surveillance at multi-disciplinary meeting * Any significant psychological conditions that may be worsened or exacerbated by participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Cancer Research and Royal Marsden Hospital

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • North Bristol NHS Trust

    NOT_YET_RECRUITING

    Bristol, BS10 5NB, United Kingdom

  • The Royal Marsden Hospital

    RECRUITING

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden Hospital

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.